Treatment considerations for patients with pemphigus during the COVID-19 pandemic - 22/04/20
Doi : 10.1016/j.jaad.2020.04.005
Hadir Shakshouk, MBBS a, b, Maryam Daneshpazhooh, MD c, Dedee F. Murrell, MD d, Julia S. Lehman, MD a, ⁎ 
a Department of Dermatology, Mayo Clinic, Rochester, Minnesota
b Department of Dermatology, Andrology and Venereology, Alexandria University, Alexandria, Egypt
c Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
d Department of Dermatology, University of New South Wales, Sydney, Australia
∗Correspondence to: Julia S. Lehman, MD, 200 First St SW, Rochester, MN 55905200 First St SWRochesterMN55905
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Wednesday 22 April 2020
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: Dr Murrell is an investigator and speaker for Roche, is an investigator for and on an advisory board for Principia Biopharma and Sanofi, and is also on an advisory board for Immune Pharmaceuticals and Lilly. Dr Lehman is an investigator for Principia Biopharma. Principia is the maker of PRN1008 which is mentioned in the article. Drs. Shakshouk and Daneshpazhooh have no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.